Summary
AMG Chart
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margins, though net selling prices and legacy drugs like Enbrel remain under pressure. Valuation analysis reveals AMGN is priced for no growth, offering 27% upside if the company achieves even modest revenue increases.
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m.
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
Amgen Inc. Dividends
 AMG 9 months ago | Other | €2.25 Per Share |
| AMG 16 May 2024 | Other | €2.25 Per Share |
| AMG 15 Feb 2024 | Other | €2.25 Per Share |
| AMG 16 Nov 2023 | Other | €2.13 Per Share |
| AMG 17 Aug 2023 | Other | €2.13 Per Share |
Amgen Inc. Earnings
| 4 Aug 2025 (57 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
| AMG 9 months ago | Other | €2.25 Per Share |
| AMG 16 May 2024 | Other | €2.25 Per Share |
| AMG 15 Feb 2024 | Other | €2.25 Per Share |
| AMG 16 Nov 2023 | Other | €2.13 Per Share |
| AMG 17 Aug 2023 | Other | €2.13 Per Share |
| 4 Aug 2025 (57 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 29 Oct 2024 Date | | - Cons. EPS | - EPS |
Amgen Inc. (AMG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Amgen Inc. ever had a stock split?
Amgen Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Bradway CEO | XHAN Exchange | US0311621009 ISIN |
| US Country | 28,000 Employees | 16 May 2025 Last Dividend | 22 Nov 1999 Last Split | 17 Jun 1983 IPO Date |
Overview
Amgen Inc. is a global leader in biotechnology, focusing on the discovery, development, manufacture, and delivery of human therapeutics. The company has a comprehensive portfolio of treatment options targeting various diseases and conditions, ranging from oncology and osteoporosis to cardiovascular diseases and inflammatory disorders. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen serves healthcare providers worldwide, including physicians' clinics, dialysis centers, hospitals, and pharmacies. Its distribution network encompasses pharmaceutical wholesale distributors and direct-to-consumer channels. Amgen’s collaborative efforts extend to several high-profile partnerships with other pharmaceutical giants, including AstraZeneca, Novartis Pharma AG, UCB, Kyowa Kirin Co., Ltd., and BeiGene, Ltd., aiming at the expansion and development of innovative therapies.
Products and Services
- Enbrel - A leading therapy for plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis.
- Otezla - Designed for adults suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease.
- Prolia - Addresses osteoporosis in postmenopausal women.
- XGEVA - Prevents skeletal-related events.
- Repatha - Reduces the risk of myocardial infarction, stroke, and coronary revascularization.
- Nplate - Treats immune thrombocytopenia.
- KYPROLIS - For relapsed or refractory multiple myeloma patients.
- Aranesp - Addresses a lower-than-normal number of red blood cells and anemia.
- EVENITY - A treatment for osteoporosis in postmenopausal for men and women.
- Vectibix - Treats patients with wild-type RAS metastatic colorectal cancer.
- BLINCYTO - For patients with acute lymphoblastic leukemia.
- TEPEZZA - Treats thyroid eye disease.
- KRYSTEXXA - Addresses chronic refractory gout.
- Additional Products - Amgen also markets Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI, covering a wide range of therapeutic areas.
Contact Information
